Μια πρωτοβουλία της GSK

Βιβλιογραφία

  1. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403
  2. Meningococcal meningitis factsheet No 141. World Health Organization website. link . Updated November 2012. Accessed October 14, 2014.
  3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-63.
  4. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
  5. European Centre for Disease Prevention and Control (ECDC).Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm, Sweden: ECDC; 2013.xs
  6. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710-3716.
  7. Parent du Châtelet I, Taha MK, Lepoutre A, Maine C, Deghmane AE, Bruhl DL. Les infections invasives à méningocoques en France en 2011: principales caractéristiques épidémiologiques. Bull Épidémiol Hebd. 2012;49-50:569-573.
  8. Stephens DS.Conquering the meningococcus.FEMS Microbiol Rev. 2007;31(1):3-14.
  9. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev.2006;19(1): 142-164.
  10. Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep.2014;40-9:160-169.
  11. European Centre for Disease Prevention and Control (ECDC).Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm, Sweden: ECDC; 2013.
  12. Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme Annual Report, 2012. Commun Dis Intell Q Rep.2013;37(3):E224-232.
  13. Organización Panamericana de la Salud.Informe Regional de SIREVA II, 2012: datos por país y por grupos de sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasavores.Washington, DC: Organización Panamericana de la Salud; 2013;2013.
  14. Grupo de Microbiologia: Neisseria meningitidis (aislamientos invasores), 2012.Instituto Nacional de Salud website. Accessed October 15, 2014.
  15. Lopez L, Sherwood J. Surveillance report: The epidemiology of meningococcal disease in New Zealand, 2013. Wellington, New Zealand: Institute of Environmental Science and Research Ltd (ESR); 2014.
  16. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134(3), 556–566 (2006).
  17. Εθνικό Κέντρο Αναφοράς Μηνιγγίτιδας, Απολογισμός Έργου 2015, σελ. 22 & 23
  18. Ereth J. The global value of vaccination. Vaccine 2003; 21: 596-600
  19. World Health Organization, Estimates of disease burden and cost-effectiveness
  20. Εθνικό Πρόγραμμα Εμβολιασμών Παιδιών και Εφήβων 2017
  21. Tzanakaki, G., (2014).Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. [online] Available at: https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-14-111 [Accessed 29 Apr. 2014]